

















Industrial plasmid DNA manufacturing processes are needed to meet the quality, 
economy, and scale requirements projected for future commercial products. NTC has 
developed an inducible fed-batch fermentation process that incorporates novel cell bank 
and fermentation process innovations that reduce plasmid mediated metabolic burden. 
This process incorporates a scalable plasmid induction profile that, in combination with 
vector backbone modifications (PAS-BH-SV40 backbone; e.g. NTC8685 Fig 3)  that 
double fermentation productivity compared to existing high copy vectors such as pVAX1 
and gWIZ, form a generic plasmid DNA production platform with plasmid yields up to 2.6 
g/L, and specific yields of 5% total dry cell weight. 
The dcm methylase recognizes the internal cytosine residues in the recognition 
sequence 5'-CC*AGG-3' or 5'-CC*TGG-3' (Fig. 3, bars). This creates 5-methyl-cytosine 
(5mC), a common mammalian pattern (CG methylation) although the dcm methylated 
cytosine is in a different sequence context in bacteria. While plasmid production yields 
and quality are similar between dcm+ and dcm- host strains, CMV promoter expression 
is reduced by dcm methylation (Fig. 4). Surprisingly, despite improved expression, dcm-
plasmid DNA is less immunogenic (Fig. 5). Our results demonstrate that it is critical to 
lock the plasmid methylation pattern (i.e. production strain) early in product development 




E. coli DH5α: F- Φ 80dlacZΔM15  Δ(lacZYA -argF) U169 recA1 endA1 hsdR17(rK-, 
mK+) phoA supE44 λ- thi-1 gyrA96 relA1; NTC48107: DH5α dcm 
Plasmid gWiz GFP: (Gene Therapy Systems) 5.8 kb, pUC origin, kanR
Plasmid NTC7485 (Williams et al., 2006, 2009) 6.2 kb, pUC origin, kanR. 
Plasmid NTC8685-EGFP, 3.9 kb, pUC origin, antibiotic-free selection (Luke et al., 2009)
Conclusions
• The combination of optimized media, reduced temperature, and nutrient limited growth 
during biomass accumulation results in high process consistency and plasmid yields up 
to 2.6 g/L (5% DCW)
• Low metabolic burden seed bank and fermentation operation enable:
– Production of previously toxic plasmids
– Production of plasmids containing unstable sequences (e.g. inverted or direct repeats 
for shRNA therapies and for viral vectors such as AAV and HIV) eliminating need for 
stabilizing cell lines
• High specific plasmid yield increases final purity and downstream purification efficiency, 
dramatically decreasing manufacturing costs
• SV40- PAS-BH backbone 2 fold higher fermentation yield than gWiz
• Processes compatible with antibiotic-free vectors (Luke et al., 2009)
• dcm methylation status affects expression and immunogenicity but not production
• dcm+ plasmid for DNA vaccination and dcm- for DNA therapeutics are recommended
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Dcm Methylation
Plasmids contain multiple dcm methylation sites (Fig. 3). The effect of dcm methylation on 
plasmid production and application was determined.
A dcm- derivative of DH5α (NTC48107) was created . Plasmid yield and quality was 
equivalent between dcm+ and dcm- strains in the low metabolic burden inducible (30-
42ºC) fed-batch fermentation process. By contrast, eukaryotic cell expression was higher 
using dcm- plasmid DNA with both the CMV-HTLV-I R (NTC8685; Fig 3) and CMV (gWIZ, 
pVAX1) promoters (Fig. 4). Paradoxically, dcm- plasmid DNA  for a NTC7485-derived  
vector encoding influenza hemagglutinin (HA) elicited lower anti-HA antibody responses in 
6-8 week old BALB/C mice after intramuscular prime boost immunization with 10 µg naked 
DNA on day 0 and 21  (Fig. 5). 
Results
Manufacturing Process
This low metabolic burden inducible (30-42ºC) fed-batch fermentation process has 
successfully been scaled to 100L and 300L, and used for GMP production. Plasmid 
yields are superior to alternative processes (Table 1; Carnes, 2005; Carnes et al. 2006; 
Carnes and Williams, 2007; Williams et al., 2009).  The temperature induction rate is 
not a critical process parameter; volumetric yields are not reduced using a slow ramp 
induction from 30ºC to 42ºC (Table 1). This insures scalability to industrial fermentors 
where temperature induction rates may be reduced compared to process scale 
bioreactors.
Reduced cell stress during the inducible fermentation process improves  stability and 
yield of deletion prone long terminal repeat and short hairpin RNA (shRNA) vectors.
Table 1: Plasmid specific yields from fed-batch fermentation 
* SD = semi-defined; D = defined
‡ (1) Williams et al., 2009, ramp induction is a slow temperature shift over 16 h
(2) Phue et al., 2008, (3) Listner et al., 2006.
Fig.3: Plasmid dcm methylation sites are shown (Blue bars) in antibiotic-free vector 
NTC8685. NTC7485 has a kanR gene swapped for the RNA-OUT sucrose selectable 
RNA (Arrow) 

















































Fig. 1 Inducible 
fed-batch 
fermentation process 
(Carnes et al., 2006)

















Fig.4: Plasmid dcm methylation reduces 
transgene expression in HEK293 (human)
Fig.5: Plasmid dcm methylation increases
transgene immunogenicity. Day 49 murine 
anti-HA humoral response after prime-boost
